Skip to main content
. 2022 Jan 11;12(1):5. doi: 10.1038/s41408-021-00603-3

Fig. 6. Co-treatment with Menin inhibitor and venetoclax or FLT3 inhibitor gilteritinib induces synergistic in vitro lethality in MOLM13 cells with isogenic TP53 mutations or TP53 knockout.

Fig. 6

A–C MOLM13 TP53-R175H, MOLM13 TP53-R248Q, and MOLM13 TP53−/− cells were treated with the indicated concentrations of SNDX-50469 and/or venetoclax for 96 h. At the end of treatment, the % non-viable cells were determined by staining with TO-PRO-3 iodide and flow cytometry analysis. Delta synergy scores were calculated by the ZIP method. Synergy scores > 1.0 indicate a synergistic interaction of the two agents in the combination. D–F MOLM13 TP53-R175H, MOLM13 TP53-R248Q, and MOLM13 TP53−/− cells were treated with the indicated concentrations of SNDX-50469 and/or gilteritinib for 96 h. At the end of treatment, the % non-viable cells were determined by staining with TO-PRO-3 iodide and flow cytometry analysis. Delta synergy scores were determined by the ZIP method. Synergy scores > 1.0 indicate a synergistic interaction of the two agents in the combination.